Pharmacokinetics and pharmacodynamics of tepoxalin after single oral dose administration to healthy volunteers.

This study was conducted to examine the pharmacokinetics and pharmacodynamics of tepoxalin in healthy volunteers, an antiinflammatory compound that inhibits cyclooxygenase and lipoxygenase. Tepoxalin was absorbed after oral administration of single doses from 35 to 300 mg, after which it was rapidly converted to an acidic metabolite, RWJ 20142, which inhibits cyclooxygenase but not lipoxygenase. The areas under the concentration-time curve (AUC) of tepoxalin and RWJ 20142 in plasma increased in a dose-dependent fashion.

Activities of human acidic fibroblast growth factor in an in vitro dermal equivalent model.

Acidic fibroblast growth factor is a potent mitogen for human dermal fibroblasts in an in vitro three-dimensional collagen matrix, the "dermal equivalent." Both cell numbers and DNA synthesis are optimally stimulated by daily doses of 1 ng/ml of the pure human mitogen in the presence of heparin, which binds to, and stabilizes, the protein. Under daily treatment by 1 ng/ml aFGF, the fibroblast mitogenic response is marked but transient, and decreases steadily when fibroblasts mature in the collagen matrix.

The interaction of interleukin 2 with its receptor in the generation of suppressor T cells in antigen-specific and antigen-nonspecific systems in vitro.

The role of interleukin-2 (IL-2) in the activation of suppressor T cells was investigated using the monoclonal antibody anti-Tac, which blocks the binding of IL-2 to the 55-kDa IL-2-binding peptide. The addition of anti-Tac during a preculture period inhibited the generation of Epstein-Barr virus (EBV)-induced suppressor T cells and of suppressor T cells induced in an antigen-specific system by a high antigen (sheep red blood cell) concentration. The cells activated by a short 2- or 7-day preculture period with EBV to become suppressor effectors were of the T8, Tac-positive phenotype.